Liu Yang, Gao Guangqiang, Yang Chun, Zhou Kun, Shen Baozhong, Liang Hongyan, Jiang Xiaofeng
Department of Clinical Biochemistry Laboratory, the 4th Affiliated Hospital of Harbin Medical University, #37 Yiyuan Street, Nangang District, Harbin 150001, China.
Heilongjiang Province Key Laboratory of Molecular Image, Harbin 150001, China.
Int J Mol Sci. 2014 Jun 12;15(6):10567-77. doi: 10.3390/ijms150610567.
Recent studies suggested an association of endothelial microRNA-126 (miR-126) with type 2 diabetes mellitus (T2DM). In the current study, we examined whether circulating miR-126 is associated with T2DM and pre-diabetic syndrome. The study included 82 subjects with impaired glucose tolerance (IGT), 75 subjects with impaired fasting glucose (IFG), 160 patients with newly diagnosed T2DM, and 138 healthy individuals. Quantitative polymerase chain reaction (qPCR) was used to examine serum miR-126. Serum miR-126 was significantly lower in IGT/IFG subjects and T2DM patients than in healthy controls (p<0.05). After six months of treatment (diet control and exercise in IGT/IFG subjects, insulin plus diet control and exercise in T2DM patients), serum miR-126 increased significantly (p<0.05). An analysis based on serum miR-126 in the sample revealed a significantly higher odds ratio (OR) for the subjects with the lowest 1/3 of serum miR-126 for T2DM (OR: 3.500, 95% confidence interval: 1.901-6.445, p<0.05) than subjects within the highest 1/3 of serum miR-126. Such an association was still apparent after adjusting for other major risk factors. The area under the curve (AUC) for the receiver-operating characteristic (ROC) analysis was 0.792 (95% confidence interval: 0.707-0.877, p<0.001). These results encourage the use of serum miR-126 as a biomarker for pre-diabetes and diabetes mellitus, as well as therapeutic response.
近期研究表明，内皮细胞微小RNA-126（miR-126）与2型糖尿病（T2DM）有关联。在本研究中，我们检测了循环miR-126是否与T2DM及糖尿病前期综合征相关。研究纳入了82例糖耐量受损（IGT）受试者、75例空腹血糖受损（IFG）受试者、160例新诊断的T2DM患者以及138例健康个体。采用定量聚合酶链反应（qPCR）检测血清miR-126。IGT/IFG受试者和T2DM患者的血清miR-126显著低于健康对照（p<0.05）。经过6个月的治疗（IGT/IFG受试者采用饮食控制和运动，T2DM患者采用胰岛素联合饮食控制和运动），血清miR-126显著升高（p<0.05）。基于样本中血清miR-126的分析显示，血清miR-126处于最低1/3的受试者患T2DM的优势比（OR）显著高于血清miR-126处于最高1/3的受试者（OR：3.500，95%置信区间：1.901 - 6.445，p<0.05）。在调整其他主要危险因素后，这种关联仍然明显。受试者工作特征（ROC）分析的曲线下面积（AUC）为0.792（95%置信区间：0.707 - 0.877，p<0.001）。这些结果支持将血清miR-126用作糖尿病前期和糖尿病以及治疗反应的生物标志物。
